Quince Therapeutics Inc
QNCX
Get informed when a big investor buys or sells
+ FollowMarket Cap$194.6M
Close$
$-0.20
100.6% downside
Current Fair Value
100.6% downsideOvervalued by 100.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $194.60 Million |
|---|---|
| Enterprise Value | $78.61 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-336 |
| Beta | 1.33 |
| Outstanding Shares | 6,132,845 |
Return
| Return on Equity | 261.79% |
|---|---|
| Return on Assets | -74.58% |
| Return on Invested Capital | -110.08% |
Valuation & Multiples
| P/E Ratio | -0.46 |
|---|---|
| PEG | -0.12 |
| Price to Sales | - |
| Price to Book Ratio | 1.87 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.36 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
$-28.02
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-1.39
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.6897▲ 59.08% |
|---|---|
| Total Calls | 170,800▼ 82.33% |
| Total Puts | 117,800▲ 23.22% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.27%▼ 0.91% |
|---|---|
| Total Invested | $6.00M▲ 173.45% |
| Investors Holding | 30▼ 21.00% |
ESG Score
No data
About Cortexyme Inc
38 employees
CEO: Dirk Thye Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP, which is in Pha...